Share ownership Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
6.030 ^USD	-3.52%		-6.51%	-31.63%

05-07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
05-06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Major shareholders: Vanda Pharmaceuticals Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 11.23 %	6,640,507	11.23 %	47 M $
Renaissance Technologies LLC 6.36 %	3,759,559	6.36 %	27 M $
STATE STREET CORPORATION 5.102 %	3,015,562	5.102 %	21 M $
AIGH Capital Management LLC 4.652 %	2,750,000	4.652 %	20 M $
Vanguard Capital Management LLC 4.198 %	2,481,491	4.198 %	18 M $
Millennium Management LLC 3.182 %	1,881,001	3.182 %	13 M $
Acadian Asset Management LLC 3.038 %	1,795,592	3.038 %	13 M $
DFA Australia Ltd. 2.924 %	1,728,089	2.924 %	12 M $
AQR Capital Management LLC 2.713 %	1,603,576	2.713 %	11 M $
Mihael Polymeropoulos 2.687 %	1,588,246	2.687 %	11 M $
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	68.48%
Individuals	5.51%
State Street Corp.	5.1%
Others	4.85%
SEI Investments Co.	0.12%
Manulife Financial Corp.	0.03%
Unknown	15.91%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	71.81%
Individuals	5.51%
Australia	2.92%
United Kingdom	1.48%
Canada	0.77%
Ireland	0.56%
Monaco	0.41%
Norway	0.23%
Germany	0.22%
Israel	0.05%
Netherlands	0.05%
China	0.04%
Spain	0.02%
Hong Kong	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees

533

Sector

Biotechnology & Medical Research

More about the company